ICAM1 and endothelial dysfunction: A post hoc analysis of clinical trial data demonstrated that tirzepatide at a dose of 15 mg significantly decreased levels of biomarkers that have been associated with endothelial dysfunction, e.g., hsCRP or ICAM-1 [33,35].